Back to feed

NCT03515798

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.

ClinicalTrials.gov
Sponsor
Institut Paoli-Calmettes
Status
Active Not Recruiting
Versions
8
Adjacent patches
7
Severity is deterministic, reproducible, uncalibrated triage metadata, not validated review priority or proven wrongdoing. New Evidence Record packages are generated for deterministic event-class membership, not by triage rank alone.

Material event timeline

5 shown
Triage: High
2019-05-06
Arm Intervention Change
v0 to v1 Pre Recruitment Inspect patch
/protocolSection/armsInterventionsModule/interventions/1/otherNames/0
/protocolSection/contactsLocationsModule/locations/0/city
/protocolSection/contactsLocationsModule/locations/0/contacts/0/name
Triage: Critical
2020-06-30
Primary Outcome Change
v2 to v3 Early Recruitment Inspect patch
/protocolSection/armsInterventionsModule/armGroups/0/description
/protocolSection/armsInterventionsModule/armGroups/0/interventionNames/1
/protocolSection/armsInterventionsModule/armGroups/1/description
Triage: High
2024-07-25
Enrollment Change
v3 to v4 Early Recruitment Inspect patch
/protocolSection/contactsLocationsModule/centralContacts
/protocolSection/contactsLocationsModule/locations/0/city
/protocolSection/contactsLocationsModule/locations/0/contacts
Triage: Low
2025-11-17
Results Reconciliation
v6 to v7 Late Recruitment Inspect patch Evidence Record
/annotationSection/annotationModule/unpostedAnnotation/unpostedEvents/0/date
/protocolSection/outcomesModule/primaryOutcomes/0/description
/protocolSection/outcomesModule/primaryOutcomes/0/measure